{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:11:12Z","timestamp":1766869872162},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,27]]},"DOI":"10.7759\/cureus.39570","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T17:20:57Z","timestamp":1685208057000},"source":"Crossref","is-referenced-by-count":1,"title":["From End-of-Life Care to Improved Quality of Life and Better Prognosis by Using Vericiguat: A Case Report From Costa Rica"],"prefix":"10.7759","author":[{"given":"Mario","family":"Speranza-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Sancho-Zumbado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso","family":"Quir\u00f3s-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref2","article-title":"Heart failure with reduced ejection fraction","volume":"77","author":"Riello RJ","year":"2021","unstructured":"Riello RJ. Heart failure with reduced ejection fraction. Cardiology. 2021, 77:772-810.","journal-title":"Cardiology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs J","year":"2021","unstructured":"Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021, 42:681-3. 10.1093\/eurheartj\/ehaa1012","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23847","article-title":"Insights into foundational therapies for heart failure with reduced ejection fraction","volume":"45","author":"McMurray JJ","year":"2022","unstructured":"McMurray JJ, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol. 2022, 45:S26-30. 10.1002\/clc.23847","journal-title":"Clin Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.10.018","article-title":"Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?","volume":"7","author":"Sharma A","year":"2022","unstructured":"Sharma A, Verma S, Bhatt DL, et al.. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?. JACC Basic Transl Sci. 2022, 7:504-17. 10.1016\/j.jacbts.2021.10.018","journal-title":"JACC Basic Transl Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10137-2","article-title":"Current and emerging drug targets in heart failure treatment","volume":"27","author":"Ghionzoli N","year":"2022","unstructured":"Ghionzoli N, Gentile F, Del Franco AM, et al.. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2022, 27:1119-36. 10.1007\/s10741-021-10137-2","journal-title":"Heart Fail Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S357422","article-title":"Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations","volume":"18","author":"Kassis-George H","year":"2022","unstructured":"Kassis-George H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations. Ther Clin Risk Manag. 2022, 18:315-22. 10.2147\/TCRM.S357422","journal-title":"Ther Clin Risk Manag"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref9","unstructured":"Merck announces U.S. FDA approval of VERQUVO\u00ae (vericiguat). (2021). Accessed. April 3, 2023: https:\/\/www.merck.com\/news\/merck-announces-u-s-fda-approval-of-verquvo-vericiguat\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2022.08.012","article-title":"Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure","volume":"26","author":"Imamura T","year":"2022","unstructured":"Imamura T, Kinugawa K. Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure. J Cardiol Cases. 2022, 26:429-31. 10.1016\/j.jccase.2022.08.012","journal-title":"J Cardiol Cases"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17781","article-title":"Soluble guanylate cyclase stimulators in heart failure","volume":"13","author":"Kansakar S","year":"2021","unstructured":"Kansakar S, Guragain A, Verma D, et al.. Soluble guanylate cyclase stimulators in heart failure. Cureus. 2021, 13:e17781. 10.7759\/cureus.17781","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rceng.2021.12.006","article-title":"Vericiguat in heart failure: from scientific evidence to clinical practice","volume":"222","author":"Gonz\u00e1lez-Juanatey JR","year":"2022","unstructured":"Gonz\u00e1lez-Juanatey JR, Anguita-S\u00e1nchez M, Bayes-Gen\u00eds A, et al.. Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp (Barc). 2022, 222:359-69. 10.1016\/j.rceng.2021.12.006","journal-title":"Rev Clin Esp (Barc)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4321\/s2254-28842019000300002","article-title":"Skin changes in patients with advanced chronic kidney disease. A systematic review. (Article in Spanish)","volume":"22","author":"Morillo-Gallego N","year":"2019","unstructured":"Morillo-Gallego N, Merino-Mart\u00ednez RM, S\u00e1nchez-Cabezas AM, Alc\u00e1ntara-Crespo M. Skin changes in patients with advanced chronic kidney disease. A systematic review. (Article in Spanish). Enferm Nefrol. 2019, 22:224-38. 10.4321\/s2254-28842019000300002","journal-title":"Enferm Nefrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13080527","article-title":"Chronic kidney disease-associated pruritus","volume":"13","author":"Agarwal P","year":"2021","unstructured":"Agarwal P, Garg V, Karagaiah P, Szepietowski JC, Grabbe S, Goldust M. Chronic kidney disease-associated pruritus. Toxins (Basel). 2021, 13:527. 10.3390\/toxins13080527","journal-title":"Toxins (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159400-from-end-of-life-care-to-improved-quality-of-life-and-better-prognosis-by-using-vericiguat-a-case-report-from-costa-rica","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:21Z","timestamp":1707508941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159400-from-end-of-life-care-to-improved-quality-of-life-and-better-prognosis-by-using-vericiguat-a-case-report-from-costa-rica"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.39570","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,27]]}}}